we conclude that chemical peritonitis is the dose-limiting toxicity of i.p . administered mitoxantrone and that a dose of 23 mg/m2 every 3 to 4 wk should be used in future phase ii trials in ovarian cancer patients with minimal residual intraabdominal and pelvic disease following second-look laparotomy .
C0230168
intraabdominal
C0030797
pelvic